Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 3, 2007, Pages 224.e1-224.e4

  Rebarber, Andrei ^a   Ferrara, Lauren A ^a   Hanley, Maryellen L ^b   Istwan, Niki B ^c   Rhea, Debbie J ^c   Stanziano, Gary J ^c   Saltzman, Daniel H ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Valley Hospital   (United States)

^c Matria Healthcare Inc   (United States)

Author keywords

17 alpha hydroxyprogesterone caproate; preterm birth prevention; recurrent spontaneous preterm delivery

Indexed keywords

HYDROXYPROGESTERONE CAPROATE;

ADULT; ARTICLE; CONTROLLED STUDY; DELIVERY; DRUG WITHDRAWAL; FEMALE; GESTATION PERIOD; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT; PREMATURE LABOR; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 33847354642     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.01.002     Document Type: Article

References (12)

1. Meis P.J., Klevanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17-alpha-hydroxyprogesterone caproate. N Engl J Med 348 (2003) 2379-2385
2. Sanchez-Ramos L., Kaunitz A.M., and Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 105 (2005) 273-279
3. Mackenzie R., Walker M., Armson A., and Hannah M.E. Progesterone for the prevention of preterm birth among women at increased risk: a systematic review and meta-analysis of randomized controlled trials. Am J Obstet Gynecol 194 (2006) 1234-1242
4. Lockwood C.J. Predicting premature delivery: no easy task. N Engl J Med 346 (2002) 282-284
5. Sexton D.J., O'Reilly M.W., Friel A.M., and Morrison J.J. Functional effects of 17alpha-hydroxyprogesterone caproate (17P) on human myometrial contractility in vitro. Reprod Biol Endocrinol 2 (2004) 80
6. Papiernick-Berkhauer E. Double blind study of an agent to prevent preterm delivery among women with increased risk. Schering Edition 4 (1970) 65-68
7. Goldstein P., Berrier J., Rosen S., Sacks H.S., and Chalmers T.C. A meta-analysis of randomized control trials of progestational agents in pregnancy. BJOG 96 (1989) 265-274
8. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: final data for 2002: National Center for Health Statistics Hyattsville, MD. 2003. Natl Vital Stat Rep; 52:no 10.
9. Escobar G.J., Clark R.H., and Greene J.D. Short-term outcomes of infants born at 35 and 36 weeks gestation: we need to ask more questions. Semin Perinatol 30 (2006) 28-33
10. Kramer M.S., Demissie K., Yang H Platt R.W., Suave R., and Liston R. The contribution of mild and moderate preterm birth to infant mortality: fetal and infant health study group of the Canadian perinatal surveillance system. JAMA 284 (2000) 843-849
11. Rubaltelli F.F., Dani C., Reali M.F., et al. Acute neonatal respiratory distress in Italy a one-year prospective study. Acta Paediatr 87 (1998) 1261-1268
12. American College of Obstetricians and Gynecologists. Use of progesterone to reduce preterm birth: ACOG committee opinion, no. 291. Obstet Gynecol 102 (2003) 1115-1116